MEGA GENOMICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.15 HKD | -0.22% |
|
+1.44% | -11.17% |
| Mar. 26 | Mega Genomics Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 12 | Mega Genomics Stockholders to Vote March 1 on Continuing Transactions | MT |
| Sales 2021 | 237M 32.73M 256M | Sales 2022 | 146M 20.11M 157M | Capitalization | 2.75B 379M 2.97B |
|---|---|---|---|---|---|
| Net income 2021 | 79M 10.9M 85.36M | Net income 2022 | -17M -2.35M -18.37M | EV / Sales 2021 * | - |
| Net cash position 2021 | 451M 62.24M 487M | Net cash position 2022 | 398M 54.86M 430M | EV / Sales 2022 | 16.1 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-128
x | Employees | 229 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 51.86% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.22% | ||
| 1 week | +1.67% | ||
| Current month | -8.68% | ||
| 1 month | +1.67% | ||
| 3 months | +1.22% | ||
| 6 months | +17.31% | ||
| Current year | -11.17% |
1 week
8.72
9.18
1 month
8.3010.02
Current year
7.9612.40
1 year
7.6812.40
3 years
7.6821.00
5 years
7.6821.00
10 years
7.6821.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Jiang
CEO | Chief Executive Officer | 44 | - |
Xiang Yi
CTO | Chief Tech/Sci/R&D Officer | 44 | - |
Xia An
COO | Chief Operating Officer | 41 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rong Yu
FOU | Founder | 52 | 21-04-21 |
Mei Ling Guo
BRD | Director/Board Member | 54 | 21-08-05 |
Lin Lin
CHM | Chairman | 48 | 21-04-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 9.15 | -0.22% | 12 400 |
| 24-04-24 | 9.17 | +1.33% | 70,800 |
| 24-04-23 | 9.05 | +1.00% | 122,400 |
| 24-04-22 | 8.96 | -0.99% | 20,200 |
| 24-04-19 | 9.05 | +0.56% | 20,000 |
Delayed Quote Hong Kong S.E., April 25, 2024 at 04:09 am EDT
More quotes
Mega Genomics Ltd is a China-based investment holding company principally engaged in genetic testing business. The Company operates its businesses through three segments. The Consumer Genetic Testing Services segment provides testing for nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, pharmacogenetic testing and infectious disease testing. The Cancer Screening Services segment provides Septin9 colorectal cancer screening test, Syndecan-2 (SDC2) colorectal cancer screening test and ring finger protein 180 (RNF180)/Septin9 gastric cancer screening test. The Other Services segment provides genetic research and analysis services to third party research institutions.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.17% | 277M | |
| -16.65% | 8.34B | |
| +39.98% | 3.59B | |
| -32.00% | 2.75B | |
| -7.88% | 2.48B | |
| -9.81% | 2.32B | |
| -13.29% | 1.79B | |
| -19.46% | 1.54B | |
| -40.57% | 1.21B | |
| +9.70% | 1.13B |
- Stock Market
- Equities
- 6667 Stock
